Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DDRD2HTR2AHTR2C
The experimentally established mechanism targets of Sertindole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertindole SCHEMBL29360085 | 1.00 | KCNH2 (1.00) | KCNH2DRD2HTR2CHRH1MLNR | |
| Sertindole SCHEMBL28600134 | 0.99 | KCNH2 (0.98) | KCNH2DRD2HTR2CHRH1MLNR | |
| SCHEMBL8638643 | 0.95 | KCNH2 (0.90) | KCNH2DRD2HTR2CHRH1MLNR | |
| SCHEMBL8636687 | 0.95 | KCNH2 (0.90) | KCNH2DRD2HTR2CHRH1MLNR | |
| SCHEMBL7382323 | 0.94 | KCNH2 (0.88) | KCNH2DRD2HTR2CHRH1MLNR | |
| SCHEMBL7435229 | 0.94 | KCNH2 (0.88) | KCNH2DRD2HTR2CHRH1MLNR | |
| SCHEMBL9149109 | 0.93 | KCNH2 (0.86) | KCNH2DRD2HTR2CHRH1MLNR | |
| SCHEMBL1135593 | 0.93 | HTR1A (0.86) | KCNH2DRD2HTR2CHRH1MLNR | |
| Sertindole SCHEMBL7363162 | 0.92 | KCNH2 (0.85) | KCNH2DRD2HTR2CHRH1MLNR | |
| Sertindole SCHEMBL7367033 | 0.91 | KCNH2 (0.84) | KCNH2DRD2HTR2CHRH1MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10130 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| WO-1997021833-A1 | METHOD OF PREDICTING A SUBJECTS RESPONSE TO NEUROLEPTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-19 | — | — | WO | claimed |
| CN-1142945-A | Medcine for curing cerebrovascular disturbance with psychonosema | SUMITOMO PHARMA (JP) | 1997-02-19 | — | — | CN | claimed |
| WO-1996031621-A2 | METHOD FOR DETERMINING THE RESPONSIVENESS OF INDIVIDUALS TO 5-HT2 RECEPTOR MODULATING AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-10-10 | — | — | WO | claimed |
| EP-0730865-A1 | Use of serotonin and dopamine receptor blockers for the treatment of mental disorders associated with cerebrovascular disease | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-09-11 | — | — | EP | claimed |
| EP-0669128-A1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-08-30 | — | — | EP | claimed |
| US-5428036-A | Psychological disorders | H. LUNDBECK A/S (DK) | 1995-06-27 | — | — | US | claimed |
| EP-0592433-A1 | SERTINDOLE PRODRUGS | H. LUNDBECK A/S (DK) | 1994-04-20 | — | — | EP | claimed |
| US-5238945-A | Without extrapyramidal side effects | H. LUNDBECK A/S (DK) | 1993-08-24 | — | — | US | claimed |
| WO-1992006089-A1 | SERTINDOLE PRODRUGS | H. LUNDBECK A/S (DK) | 1992-04-16 | — | — | WO | claimed |
| EP-0392959-A2 | Use of sertindole for the treatment of schizophrenia | H. LUNDBECK A/S (DK) | 1990-10-17 | — | — | EP | claimed |